 The primary objective of this study is to assess the safety, tolerability and efficacy of atomoxetine as determined by the change in the ADHD-RS-IV Total score compared to placebo in the symptomatic treatment of patients diagnosed with Attention-DeficitHyperactivity Disorder by DSM-IV ADHD-NOS criteria occurring as a neuropsychological late-effect of chemotherapy used to treat Acute Lymphocytic Leukemia ALL. 